Batata A, Shen B
Department of Pathology, Cox Institute, Wright State University School of Medicine, Dayton, Ohio 45429.
Cancer. 1992 Nov 15;70(10):2436-43. doi: 10.1002/1097-0142(19921115)70:10<2436::aid-cncr2820701009>3.0.co;2-c.
The French-American-British group's proposal for the classification of chronic lymphoid leukemias is unique at this time. Testing, expanding, and adding to the theory by immunophenotyping will help to additionally characterize this group of diseases.
Peripheral blood samples from 242 patients with chronic lymphoid leukemias were analyzed for immunologic evaluation of the following subtypes: typical chronic lymphocytic leukemia (CLL), 189; CLL with pleomorphic lymphocytes (CLL-pleo), 19; CLL of mixed cell type (CLL/PL), 20; prolymphocytic leukemia (PLL), 22; hairy cell leukemia (HCL), 10; HCL-variant, 1; and splenic lymphoma with villous lymphocytes, 1.
The phenotype of CLL and CLL-pleo was weak surface immunoglobulin (SIg) with positive results of mouse rosettes (MR+), CD5+, and CD22-. Of PLL and HCL, it was strong SIg, MR-, CD5-, and CD22+. By analyzing the four markers and accepting the relevant results of two or more as sufficient for diagnosis, all cases (100%) of CLL, CLL-pleo, PLL, and HCL were diagnosed. CLL/PL showed the phenotype of CLL in 66.67% and of PLL in 33.33% of patients. The frequency of cases with weak fluorescence in decreasing order was CLL, CLL-pleo, CLL/PL, and PLL and HCL. The same sequence applied to the mean percentage of mouse rosette-forming cells and CD5 cells, but the sequence was reversed for CD22 cells.
SIg intensity, MR, CD5, and CD22 constitute the minimum number of immune markers for the differential diagnosis of the subtypes of chronic lymphoid leukemia. The frequency of the four markers among the subtypes suggested that CLL and CLL-pleo have identical phenotypes and that the five subtypes follow a continuous range of B-cell differentiation from early mature (CLL and CLL-pleo) to late mature pre-plasma cell stages (PLL followed by HCL), with CLL/PL of intermediate maturity.
法美英协作组提出的慢性淋巴细胞白血病分类方案在当前独具特色。通过免疫表型分析对该理论进行检验、拓展和补充,将有助于进一步明确这组疾病的特征。
对242例慢性淋巴细胞白血病患者的外周血样本进行分析,以对以下亚型进行免疫学评估:典型慢性淋巴细胞白血病(CLL),189例;伴有多形性淋巴细胞的CLL(CLL-pleo),19例;混合细胞型CLL(CLL/PL),20例;幼淋巴细胞白血病(PLL),22例;毛细胞白血病(HCL),10例;变异型HCL,1例;以及伴有绒毛状淋巴细胞的脾淋巴瘤,1例。
CLL和CLL-pleo的表型为弱表面免疫球蛋白(SIg)、小鼠玫瑰花结试验阳性(MR+)、CD5+和CD22-。PLL和HCL的表型为强SIg、MR-、CD5-和CD22+。通过分析这四种标志物,并将两种或更多标志物的相关结果作为诊断依据,所有CLL、CLL-pleo、PLL和HCL病例(100%)均得以确诊。CLL/PL患者中66.67%表现为CLL的表型,33.33%表现为PLL的表型。荧光较弱病例的发生率从高到低依次为CLL、CLL-pleo、CLL/PL以及PLL和HCL。小鼠玫瑰花结形成细胞和CD5细胞的平均百分比也呈现相同顺序,但CD22细胞的顺序相反。
SIg强度、MR、CD5和CD22构成了慢性淋巴细胞白血病各亚型鉴别诊断所需的最少免疫标志物数量。各亚型中这四种标志物的发生率表明,CLL和CLL-pleo具有相同的表型,且这五个亚型遵循从早期成熟(CLL和CLL-pleo)到晚期成熟前浆细胞阶段(PLL,随后是HCL)的连续B细胞分化过程,CLL/PL处于中间成熟阶段。